A Multicenter Assessment of ALD403 in Chronic Migraine

Inclusion Criteria:

- Diagnosis of migraine at ≤ 35 years of age with history of chronic migraine ≥ 1 year

- During the 28 day screening period, must have ≥ 15 headache days of which ≥ 8 days
were assessed as migraine days with at least 5 migraine attacks as recorded in the
eDiary

- Headache eDiary was completed on at least 22 of the 28 days prior to randomization

Exclusion Criteria:

- Confounding pain syndromes (e.g. fibromyalgia, chronic low back pain, complex regional
pain syndrome) or any pain syndrome that requires regular analgesia

- Psychiatric conditions that are uncontrolled and untreated, including conditions that
are not controlled for a minimum of 6 months prior to screening.

- History or diagnosis of complicated migraine (ICHD-III beta version, 2013), chronic
tension-type headache, hypnic headache, cluster headache, hemicrania continua, new
daily persistent headache, migraine with brainstem aura, sporadic and familial
hemiplegic migraine

- Unable to differentiate migraine from other headaches

- Subject has received botulinum toxin for migraine or for any other medical/cosmetic
reasons requiring injections in the head, face, or neck within 4 months prior to
screening.

- Have any clinically significant concurrent medical condition

- Receipt of any monoclonal antibody treatment within 6 months of screening (within or
outside a clinical trial)

- Previously dosed with ALD403 or any monoclonal antibody targeting the CGRP pathway